Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 5 results

ea0092ps2-15-09 | Hyperthyroidism | ETA2023

Long-term follow-up after antithyroid drug treatment withdrawal in patients with the first episode of graves` disease: a retrospective cohort study in spain

Meneses Diego , Sanchez Lechuga Begona , Velez Romero Maria , Sierra Poyatos Roberto , Vazquez Martinez Clotilde , Cardenas Salas Jersy

Background: Despite a high relapse rate, antithyroid drugs (ATDs) remain the first-line therapy of Graves’ disease (GD). Long-term follow-up studies of GD in Spain are scarce. Our aims were to identify clinical differences between patients who relapsed vs those who attained remission and to describe the relapse rate of GD after ATD withdrawal.Methods: We analyzed patients with the first episode of GD who were treated with ATDs during 2010 - 2020, in...
3 shares

ea0063p981 | Diabetes, Obesity and Metabolism 3 | ECE2019

Effectiveness and tolerance of liraglutide and bupropión/naltrexone: clinical experience

Cardenas-Salas Jersy Jair , Luca Bogdana Luiza , Aliaga-Verdugo Alberto , Montoya-Alvarez Teresa , Gutierrez-Medina Sonsoles , Sierra-Poyatos Roberto , Sanz-Pastor Maria Alba Galdon , Martinez Clotilde Vazquez

Introduction: Different pharmacological therapies for obesity have become available in the last years. It is important to know their effectiveness in real-world practice and their acceptance among patients.Objectives: To analyze the anthropometric changes, daily dosis, side effects and treatment withdrawal in patients treated with Liraglutide or Naltrexone/Bupropion in clinical practice.Material and methods: Retrospective descripti...
0 shares

ea0090p336 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Oral Semaglutide Improves Metabolic Outcomes in Type 2 Diabetes: A Spain-based Study

Casado Carlos , Jair Cardenas Salas Jersy , Miguel Sierra Poyatos Roberto , Montoya Alvarez Teresa , Meneses Gonzalez Diego , Gabriel Ruiz Sanchez Jorge , Luiza Luca Bogdana , Sanchez Lechuga Begona , de los Angeles Velez Romero Maria , Vazquez Martinez Clotilde

Objectives: To evaluate the changes in HbA1c, basal glucose, weight, and lipid profile in patients with type 2 diabetes after starting oral semaglutide.Methods: This study was conducted in Madrid, Fundación Jiménez Díaz, Infanta Elena and General de Villalba hospitals. A total of 75 patients with type 2 diabetes were included. The mean age was 62.0±10.5 years and 60% were men. The mean duration of diabetes was 7.3±6.6 years, and 66.7...
1 shares

ea0070aep462 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Effects of semaglutide on glycemic control and body composition in patients with type 2 diabetes mellitus and obesity in a real life setting in spain

luiza luca Bogdana , Miguel Sierra Poyatos Roberto , Cardenas Jersy , Sanchez Gomez Nancy , Jesus Silva Rodriguez Maria , Modroño Mostoles Naiara , Montoya Alvarez Teresa , Sanchez Lopez Raquel , Cruces Vega Eva , Estrella Alicia , Barrio Pilar , Sanchez Lechuga Begoña , Gonzalo Montesinos Irene , Jose De la Cruz Fernandez Maria , Perez Alvarez Enrique , Vazquez Martinez Clotilde

Introduction: Semaglutide is a GLP1 receptor agonist (GLP1RA) recently approved in Spain for the treatment of Type 2 Diabetes (T2D) and the National Health Service finances it for patients with T2D and body mass index (BMI) > 30 with a poor metabolic control with metformin.Objectives: Evaluate the effects of Semaglutide on glycemic control and body composition in patients with T2D (PwT2D) and obesity after 6 months of use in a real life setting.<...
0 shares

ea0070ep197 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Real world data of Type 2 Diabetes Mellitus (T2DM) obese patients using another GLP1 receptor agonist (GLP1–RA) and switching to Semaglutide in Spain

Cardenas Jersy , Sanchez Gomez Nancy , Miguel Sierra Poyatos Roberto , Luiza Luca Bogdana , Modroño Mostoles Naiara , Montoya Alvarez Teresa , Silva Rodriguez Maria Jesus , Ortega Juaristi Maite , Meneses González Diego , De Los Angeles Gonzalo Redondo Maria , Galdon Sanz–Pastor Alba , Ruiz Sanchez Jorge , De La Paz Gómez Montes María , Cruces Vega Cristina , Vazquez Martinez Clotilde

Objectives: Semaglutide was approved for the treatment of T2DM patients with a body mass index (BMI) > 30kg/m2 by the Spanish National Health Service in May 2019. We evaluate clinical outcomes of patients on previous treatment with any another GLP1–RA that switch to Semaglutide.Material and Methods: Retrospective analysis. Sixty–five T2DM patients were included. Demographic data, anthropometric, systolic blood pressure (SBP), d...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more